Intercept Pharmaceuticals Inc (ICPT)
16.70
+0.04 (+0.24%)
USD |
NASDAQ |
Aug 10, 16:00
17.92
+1.22 (+7.31%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 497.63M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -0.30% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.458 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -1.930 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 91.20% |
News
Headline
Wire
Time (ET)
MT Newswires
08/08 07:12
Yahoo
08/05 04:27
MT Newswires
08/04 09:17
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/03/2022* | -- | Results | Q3 2022 | -- | 5.93 | -- | |
| 11/03/2022* | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.68 | -0.39 | -72.88% | |
| 08/03/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/06/2022 | -- | Results | Q1 2022 | -0.58 | -0.76 | 23.28% | |
| 05/06/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/02/2022 | -- | Results | Q4 2021 | -1.23 | -0.81 | -51.85% | |
| 03/02/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. |
| URL | https://www.interceptpharma.com |
| Investor Relations URL | https://ir.interceptpharma.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 03, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 10, 2022.
Fundamentals
| Revenue (TTM) | 345.57M |
| Total Expenses (TTM) | 396.29M |
| Net Income (TTM) | -64.72M |
| Total Assets (Quarterly) | 498.60M |
| Total Liabilities (Quarterly) | 868.43M |
| Shareholders Equity (Quarterly) | -369.83M |
| Cash from Operations (TTM) | 2.778M |
| Cash from Investing (TTM) | -83.73M |
| Cash from Financing (TTM) | -1.817M |
Ratings
Profile
Edit
| Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. |
| URL | https://www.interceptpharma.com |
| Investor Relations URL | https://ir.interceptpharma.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 03, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| CIG4926 | 10.33M USD | 5.45% |
| F000015ZK6 | 230.00 USD | 2.30% |
| FTMSX | 192304.0 USD | 1.60% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ICPT Tweets |